KEYTRUDA® (pembrolizumab) KEYNOTE-A18 clinical data presentation
KEYTRUDA® (pembrolizumab) KEYNOTE-A18 clinical data presentation
Prescribing Information (United Kingdom) [External link]
Access the KEYNOTE-A18 clinical data presentation above to find out more about the trial design and study outcomes, including efficacy and safety.
Click on the resource to view.
KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III – IVA locally advanced cervical cancer in adults who have not received prior definitive therapy. 1
Refer to the Summary of Product Characteristics and Risk Minimisation Materials available on the emc website before prescribing, in order to help reduce the risk associated with KEYTRUDA.
For more information about KEYTRUDA® (pembrolizumab) in locally advanced cervical cancer, click on the product page button below:
Reference
- KEYTRUDA Summary of Product Characteristics
Abbreviations
FIGO: International Federation of Gynecology and Obstetrics.
Supporting documentation
Prescribing Information (United Kingdom) [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
